OPPI India

76 years ago, India was born free. Since then, our country has undertaken a remarkable journey of progress, innovation, and development in almost every field, including healthcare and pharmaceuticals. Along with our member companies, we have been working relentlessly to ensure that no corner of our nation is left untouched by access to quality healthcare. We’ve been investing in modern treatments, expanding research centres in partnership with the government, and providing access to new vaccines and therapies to those in need. As we progress towards India@100, our commitment to the country’s healthcare needs grows stronger. Together, we will continue to enable freedom from diseases, inaccessibility of medicines, and unmet medical needs. Happy #IndependenceDay! #BharatKeLiye  Ministry of Health and Family Welfare, Government of India

Be ready for an event that will propel India’s transformation from the pharmacy of the world to a pharma powerhouse to the world! Visionaries, innovators, regulators, academia and industry leaders will join forces to accelerate India’s shift toward a value-driven pharma industry, shaping its future as a global leader and envisioning the path ahead for India Pharma @2047. Stay tuned for more updates! #OPPIAnnualSummit #BharatKeLiye #ViksitBharat #Healthcare #Innovation #Innovators #HealthyNation #NationBuilding #PharmaWorld #Pharmacy #Regulators #Visionaries #IndianPharma #StayTuned 

In a recent article for Express Pharma, Anil Matai, Director General, OPPI, underscores the necessity for collaboration between the government and industry bodies. He believes that such partnerships are crucial for creating skill development programs tailored to the complexities of modern drug development. He also highlights the significance of utilizing cutting-edge technologies like #AI, data analytics, and #biotechnology, which are transforming drug discovery and manufacturing. These advancements require a #skilled workforce prepared to navigate the evolving landscape of the #pharmaceutical industry. Read more: https://lnkd.in/gDCccY2W

Novartis India’s Global Capability Center delivers top-tier support across various functions, including #drug development, business services, and manufacturing supply chain. This center plays a critical role in driving the company’s growth while fulfilling its mission to improve and extend patients' lives. #ValueOfInnovation #GCC

Gen AI is empowering Global Capability Centres in India to tackle key challenges in the healthcare ecosystem. Anil Matai, Director General, OPPI, shares insights in his latest blog on how the technology is driving these centres to develop solutions and operational efficiency that create a global impact. Read more at: https://lnkd.in/dmtenxyK #BharatKeLiye #GenAI #Technology #Innovation #Healthcare

India is #polio-free, but we must stay vigilant by ensuring every child gets #vaccinated. OPPI and our member companies are committed to improving healthcare outcomes, keeping patients at the core. Let’s protect the #future! #WorldPolioDay #BharatKeLiye 

OPPI recently hosted a meeting with International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the EFPIA - European Federation of Pharmaceutical Industries and Associations. The joint bilateral discussions included collaborations in regulatory set ups including on reliance and accelerated regulatory pathways. #BharatKeLiye Anil Matai Janis Bernat Finny Liu

We are delighted to share that OPPI hosted a side meeting alongside the 19th International Conference of Drug Regulatory Authorities (ICDRA). In this meeting Anil Matai, Director General OPPI, engaged with senior officials of the Central Drugs Standard Control Organization and members of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the EFPIA - European Federation of Pharmaceutical Industries and Associations. The entire discussion centered on important topics such as improving the ease of doing business, commending CDSCO for its progressive regulatory decisions, and promoting reliance and expedited regulatory pathways. Dr. Annam Visala, Joint Drug Controller (India), CDSCO  Dr. Chandrashekar Ranga, Joint Drug Controller (India), CDSCO  Dr. Rubina Bose, Deputy Drugs Controller (India), CDSCO Janis Bernat, Director, Scientific and Regulatory Affairs, IFPMA Finny Liu, APAC Regional Regulatory Policy Lead, PDR, Roche Singapore Pte Ltd #BharatKeLiye #CDSCO #IFPMA #EFPIA

OPPI India had the honor of meeting with Union Minister of Commerce and Industry, Mr. Piyush Goyal, to discuss how the #pharmaceutical sector can drive progress. Our discussions centered on key areas such as advancing #innovation, expanding patient access, generating employment, and enhancing skills to build a stronger India. #BharatKeLiye Anil Matai

MSD’s Global Capability Centre leads the way in research and manufacturing, providing cutting-edge #healthcare solutions that advance the prevention and treatment of life-threatening diseases. By harnessing India’s talented workforce, MSD is establishing the country as a key global hub for API production. #ValueOfInnovation #BharatKeLiye